Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Saralasin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.49 |
| ▸ | CALCR | P30988 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Saralasin SCHEMBL18699973 | 1.00 | C5AR1 (0.59) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Saralasin SCHEMBL2199404 | 0.99 | C5AR1 (0.58) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Saralasin SCHEMBL125013 | 0.99 | C5AR1 (0.58) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| SCHEMBL19780882 | 0.98 | C5AR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Saralasin SCHEMBL2200145 | 0.98 | C5AR1 (0.57) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| SCHEMBL34470047 | 0.97 | C5AR1 (0.62) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Trv-120027 SCHEMBL11023969 | 0.97 | AGTR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Trv-120027 SCHEMBL19780884 | 0.97 | AGTR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Trv-120027 SCHEMBL17274208 | 0.97 | AGTR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR | |
| Trv-120027 SCHEMBL11024001 | 0.97 | AGTR1 (0.60) | C5AR1AGTR1EPHA2AGTR2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3901 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| EP-4601697-A2 | A FORMULATION FOR ORAL DELIVERY OF PEPTIDES AND BIOSIMILARS FOR SYSTEMIC ABSORPTION AND METHOD OF MANUFACTURING THE SAME | NBI Biosciences Pvt Ltd (IN) | 2025-08-20 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1995033454-A1 | UTERINE FIBROID TREATMENT | THE UNIVERSITY OF BIRMINGHAM (GB) | 1995-12-14 | — | — | WO | claimed |
| WO-1995022992-A2 | METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS | CHIRON CORP (US) | 1995-08-31 | — | — | WO | claimed |
| WO-1995022992-A1 | METHOD AND COMPOSITIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE AGENTS | CHIRON CORPORATION (US) | 1995-08-31 | — | — | WO | claimed |
| WO-1992013564-A1 | COMBINATION OF AN ANGIOTENSIN II ANTAGONIST OR RENIN INHIBITOR WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR | SCHERING CORPORATION (US) | 1992-08-20 | — | — | WO | claimed |
| EP-0498361-A2 | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor | SCHERING CORPORATION (US) | 1992-08-12 | — | — | EP | claimed |
| US-5036048-A | Angiotensin II receptor blockers as antiglaucoma agents | SCHERING CORPORATION (US) | 1991-07-30 | — | — | US | claimed |
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | claimed |
| US-3932624-A | Method for prolonging the inhibitory effect of saralasin on angiotensin II | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-01-13 | — | — | US | claimed |